-->

Company Registry

Zata Pharmaceuticals Inc
Profile last edited on: 3/13/2020

Oligotherapeutics and antipathogens
Year Founded
2009
First SBIR Year
2014
Latest SBIR Award
2021
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

60 Prescott Street
Worcester, MA 01605
Multiple Locations:   
Congressional District:   02
County:   Worcester

Public Profile

Zata Pharmaceuticals Inc is developing a platform technology that enables a novel class of oligotherapeutics - synthetic compounds involved in the treatment of cancer, infections, and genetic diseases as well as in scarless wound healing. Founded by Dr. David R. Tabatdze and Dr. Paul Zamecnik, a co-discoverer of tRNA and a pioneer of oligotherapy (antisense chemotherapy). Zata has worked on development of a nucleic acid platform for the self-delivery of oligotherapeutics and has also developed antipathogen compounds capable of inactivating existing and emerging blood borne infectious agents in pre-transfusion blood products. ZATA is focused on two major programs: ZAP-D – Current blood safety approach is based on a large number of tests that do not provide 100% safety. ZAP-D (synthetic compound_ provides full safety by selective elimination of genomic molecules of the pathogens if presented in donated blood. ZATA’S OLIGOTHERAPEUTICS (OT). Cell membranes do not allow for the cellular uptake of negatively charged OT currently used. Low cellular penetration caused multiple OT to fail over the last couple of decades. ZATA’s technology solves this problem.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
No
Public/Private
Privately Held
Stock Info
---
IP Holdings
1-4

Awards Distribution by Agency

Key People / Management

  David R Tabatadze -- Co-Founder, President and CEO

  William Apruzzese -- Director of Clinical Development

  Malay Raychowdhury -- Director of Advanced Research

  Paul Weiner -- Chairman

  Milka Yanachkova -- Senior Scientist

  Paul Zamecnik -- Co-Founder

  Boris Zavizion -- Director Of Biology, Director of Pre-Clinical

SBIR firms in the news

There are no news available.